The collaboration combines the unique capabilities of Feldan’s Shuttle platform and Elasmogen’s soloMER™ technology to develop the delivery system and binding domains for two undisclosed intracellular targets for Amgen.
Elasmogen develops new medicines based on antibody-like molecules isolated from sharks, called VNARs (variable new-antigen receptors). VNARs are found in sharks as part of their immune system and have a similar protective role to antibodies present in the human body.
The fact that VNARS are the smallest molecules of this type identified so far in the animal kingdom (evolved over 400 million years and one twelth of a human antibody) makes them unique from a biotechnology perspective. This small size allows them to access parts of the body our antibodies can’t reach, including deep inside solid cancer tumours.
The aim of the research agreement with Amgen is to accelerate the development of a new class of therapeutics.